

Resource Summary Report

Generated by [NIF](#) on Sep 11, 2026

Addis Ababa University Center for Innovative Drug Development and Therapeutic Trials for Africa Core Facility

RRID:SCR_028125

Type: Tool

Proper Citation

Addis Ababa University Center for Innovative Drug Development and Therapeutic Trials for Africa Core Facility (RRID:SCR_028125)

Resource Information

URL: <https://www.cdt-africa.org/>

Proper Citation: Addis Ababa University Center for Innovative Drug Development and Therapeutic Trials for Africa Core Facility (RRID:SCR_028125)

Description: World Bank-supported regional center of excellence focused on building capacity for clinical trials, and developing novel vaccines, diagnostics, and therapeutics. Provides training in clinical trials and translational medicine, to foster homegrown health solutions. Training researchers, scientists, and clinical trial staff across Africa in trial management, data management, and scientific writing.

Abbreviations: CDT-Africa

Synonyms: Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa)

Resource Type: access service resource, core facility, service resource

Keywords: ABRF

Resource Name: Addis Ababa University Center for Innovative Drug Development and Therapeutic Trials for Africa Core Facility

Resource ID: SCR_028125

Record Creation Time: 20260314T064515+0000

Record Last Update: 20260905T133606+0000

Ratings and Alerts

No rating or validation information has been found for Addis Ababa University Center for Innovative Drug Development and Therapeutic Trials for Africa Core Facility.

No alerts have been found for Addis Ababa University Center for Innovative Drug Development and Therapeutic Trials for Africa Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Ali AM, et al. (2023) Genetic variants of genes involved in thiopurine metabolism pathway are associated with 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia patients from Ethiopia. *Frontiers in pharmacology*, 14, 1159307.

Ali AM, et al. (2023) Incidence and determinants of hematotoxicity in acute lymphoblastic leukemia children who received 6-mercaptopurine based maintenance therapy in Addis Ababa, Ethiopia. *PloS one*, 18(6), e0286544.